Skip to content
Skip to search
Skip to footer
- ACE-MOVE: Registry focusing on diagnosis and innovative treatments to improve outcomes in patients with amyloidosis. Joshua Mitchell, MD. Washington University.
- AG10 OLE: An open-label extension and safety monitoring study of acoramidis in participants with symptomatic transthyretin amyloid cardiomyopathy who completed the phase 3 ATTRIBUTE-CM trail. Joshua Mitchell, MD. Eidos Therapeutics.
- APOLLO-B: Phase 3 study evaluating the efficacy and safety of Patisiran in patients with transthyretin amyloidosis with cardiomyopathy. Joshua Mitchell, MD. Alnylam Pharmaceuticals.
- ATRIUM: Phase 3 study evaluating the efficacy and safety of Abatacept in hospitalized participants with Immune checkpoint inhibitor associated myocarditis. Joshua Mitchell, MD. Massachusetts General Brigham/Bristol Myers Squibb.
- ATTRIBUTE-CM: Phase 3 study on the efficacy and safety of AG10 in subjects with symptomatic transthyretin amyloid cardiomyopathy. Joshua Mitchell, MD. Eidos Therapeutics.
- BIOMARKER ANALYSIS IN PATIENTS WITH CANCER: Prediction of cancer therapeutics related cardiac dysfunction and major adverse cardiovascular events in cancer patients treated with potentially cardiotoxic agents. Joshua Mitchell, MD. Washington University.
- CARDIAC REHAB: Cardiac Rehabilitation for patients receiving radiation therapy for thoracic cancers. Shahed Badiyan, MD. The Foundation for Barnes Jewish Hospital.
- CARDIOTTRANSFORM: Phase 3 study evaluating the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Joshua Mitchell, MD. Ionis pharmaceuticals, Inc.
- CARISMA: Phase 2 study evaluating tyrosine kinase inhibitor risk-reduction with intensive systolic BP management. Joshua Mitchell, MD. ECOG-ACRIN Cancer Research Group.
- CARING: Continuous versus intermittent cardiac electrical monitoring in patients with acute promyelocytic leukemia or solid tumor cancer being treated with arsenic trioxide or capecitabine. Joshua Mitchell, MD. Washington University.
- CLARITY: A study of patients with histologically confirmed, advanced non-small cell lung cancer receiving radiation therapy evaluating biomarkers of cardiovascular stress, inflammation and vascular dysfunction. Joshua Mitchell, MD. National Heart, Lung and Blood Institute.
- ICI ASSOCIATED MYOCARDITIS: Characterization of heart tissue from patients with immune checkpoint inhibitor-associated myocarditis. Jesus Jimenez, MD, Ph.D. Washington University.
- PATISIRAN EXPANDED ACCESS: Expanded access protocol to provide patisiran to patients with transthyretin-mediated amyloidosis with cardiomyopathy. Joshua Mitchell, MD. Alnylam Pharmaceuticals, Inc.
- PROACT: Evaluation of MyoStrain® sequences with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer. Joshua Mitchell, MD. Myocardial Solutions, Inc.
- SURVIVE Registry: Cardiovascular toxicity in cancer and improvement in recovery registry. Joshua Mitchell, MD
- TACTIC: A study of patients with HER-2 positive breast cancer receiving HER-2 directed therapy evaluating the timing of carvedilol initiation as an agent to reduce the incidence of LVEF decline. Joshua Mitchell, MD. Mayo Clinic
- Transcutaneous Pacing (TCP) Pilot Study – EP Lab. Marye Gleva MD. Washington University
- RESTART Study: Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion in Afib patients. Daniel Cooper MD. Washington University
- LIBREXIA-AF: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation. Marye Gleva MD. Washington University
- VIBRANT-AF: Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation. Daniel Cooper MD. Washington University